search
Back to results

Safety and Tolerability of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation

Primary Purpose

Gene Mutation

Status
Enrolling by invitation
Phase
Early Phase 1
Locations
China
Study Type
Interventional
Intervention
RAG-17
Sponsored by
Beijing Tiantan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gene Mutation focused on measuring RAG-17, SOD1 Gene Mutation, Amyotrophic Lateral Sclerosis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients who are judged by professional medical staff to still be able to carry out the clinical trial project cycle; 18 years old ≤ age ≤ 75 years old, males or females; ALS patients with confirmed SOD1 gene mutations document (known SOD1 mutation sites and related disease progression have been reported); Forced vital capacity ≥ 80% of predicted vital capacity during the screening period; Diagnosis of confirmed or probable familial or sporadic ALS in accordance with the revised EI Escorial diagnostic criteria for amyotrophic lateral sclerosis of the World Federation of Neurology; The patient or patient's legal representative clearly understands and voluntarily participates in the study and signs the informed consent form; Subjects (including male subjects) are willing to have no birth plan and voluntarily take effective contraceptive measures during the entire study period and within 3 months after the end of the study, and have no plan to donate sperm or eggs. Exclusion Criteria: Patients with SOD1 mutations occurring at nucleotides 44 to 66 (calculated from the start of SOD1 protein translation), patients with P.F21C mutation; Patients who have previously received or are currently receiving Tofersen treatment; HIV test positive or history of positive tests; Positive hepatitis C virus antibody or history of positive tests; Active hepatitis B infection (positive hepatitis B surface antigen and/or positive hepatitis B core antibody); Have used other investigational drugs within 1 month or within 5 drug half-lives; Diseases and deformities of the lumbar spine; Have other conditions known to be associated with motor neuron dysfunction that may confuse or obscure an ALS diagnosis; Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent; With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value≥2.0 times the upper limit of normal value or AST value≥2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE≥1.5 times the upper limit of normal value or eGFR<40mL/min/1.73m2; severe cardiac insufficiency refers to NYHA class 3-4); Permanently dependent on ventilator-assisted ventilation; History of alcohol and drug abuse; Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant; Patients participating in other clinical trials or using other biological agents, drugs or devices under investigation; Patients who have received any vaccinations within 28 days; Contraindications to MRI (eg, claustrophobia); Unable to be cooperative and complete the follow-up due to other reasons.

Sites / Locations

  • Beijing Tiantan Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

RAG-17

Arm Description

Doses of RAG-17 will range from a minimum of 60 mg to the maximum tolerated dose (MTD). Dosing once every two weeks, starting from 60 mg, with dose escalation. After reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months.

Outcomes

Primary Outcome Measures

Adverse events (AE) and serious adverse events (SAE)
The incidence of adverse events (AE) and serious adverse events (SAE) within 180 days after RAG-17 treatment, and number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V5.0
Clinical laboratory examination index
Monitor the abnormal change of clinical laboratory Index generated from general examination results before RAG-17 treatment, and within 180days after RAG-17 treatment, which including blood testing and urine testing. Eventually to determine the safety and tolerability of RAG-17 on adult ALS patients.
Physiological Parameter-Vital Sign: Body Temperature
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including body temperature in degree Celsius.
Physiological Parameter-Vital Sign: Pulse Rate
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including pulse rate in beats per minute.
Physiological Parameter-Vital Sign: Respiration Rate
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including respiration rate in breaths per minute.
Physiological Parameter-Vital Sign: Blood Pressure
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including blood pressure in mmHg.
Physiological Parameter-Vital Signs: Height, Hip Circumference and Waist
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital signs that are measured including height, hip circumference and waist in centimeter.
Physiological Parameter-Vital Signs: Weight
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including body weight in kilogram.
Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)
Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) is a questionnaire-based scale that is used to measure the change in functional impairment of adult ALS patients within 180 days after RAG-17 treatment. ALSFRS-R scale measures 12 aspects of physical function, and each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0.
Neurological examinations
Incidence rate of abnormalities in neurological examinations within 180 days after RAG-17 treatment
Heart circulatory system examinations
Incidence rate of abnormalities in heart circulatory system examinations within 180 days after RAG-17 treatment
Respiratory system examinations
Incidence rate of abnormalities in respiratory system examinations within 180 days after RAG-17 treatment
Abdominal examinations
Incidence rate of abnormalities in abdominal examinations within 180 days after RAG-17 treatment
ECG results
Incidence rate of abnormalities in ECG results within 180 days after RAG-17 treatment

Secondary Outcome Measures

SOD1 protein levels
Changes of SOD1 protein levels in cerebrospinal fluid from baseline on day 1, day 15, day 29, day 60, day 120, day 180 and day 240 of adult ALS patients after RAG-17 treatment
Plasma neurofilament light (NFL) levels
Changes in plasma neurofilament light (NFL) levels from baseline on day 1, day 15, day 29, day 60, day 120, day 180 and day 240 in adult ALS patients after RAG-17 treatment
Pharmacokinetic Changes of RAG-17
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Maximum Observed Concentration (Cmax) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Pharmacokinetic Changes of RAG-17
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Time to Reach Maximum Observed Concentration (Tmax) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Pharmacokinetic Changes of RAG-17
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Pharmacokinetic Changes of RAG-17
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Pharmacokinetic Changes of RAG-17
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Apparent Terminal Elimination Half-life (t1/2) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Mechanical ventilation
Time to invasive mechanical ventilation in adult ALS patients treated with RAG-17
Death
Time of death in adult ALS patients treated with RAG-17

Full Information

First Posted
May 7, 2023
Last Updated
June 11, 2023
Sponsor
Beijing Tiantan Hospital
Collaborators
Ractigen Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT05903690
Brief Title
Safety and Tolerability of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation
Official Title
Safety and Tolerability of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
May 22, 2023 (Actual)
Primary Completion Date
February 28, 2024 (Anticipated)
Study Completion Date
February 28, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Tiantan Hospital
Collaborators
Ractigen Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of RAG-17 in adult amyotrophic lateral sclerosis (ALS) patients with SOD1 mutation. Patients will receive drug treamtent via dose escalation which ranging from minimum of 60 mg to the maximum tolerated dose (MTD), after reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months. The duration of this study is two years.
Detailed Description
This study is an open-label, single center, first-in-Human dose escalation study to evaluate the safety, tolerability and pharmacokinetics of RAG-17 in adultamyotrophic lateral sclerosis (ALS) patients with SOD1 mutation via dose escalations. Patients will receive 60mg of RAG-17 firstly, within 14 days after the first administration, the subject has no adverse event (AE) and serious adverse event (SAE), the subject can accept dose escalation every 30mg/14 days of observation period. 3 to 4 dose escalations are planned to reach the dose limiting toxicity (DLT), with optimal doses for continual 6-month treatment cycles. For the dose of subsequent continuous treatment, an optimal dose between the safe dose and the maximum tolerated dose (MTD) is selected as the continuous treatment dose. SAS software is used for safety analysis. The sample size of this study is 6 ALS patients with SOD1 mutation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gene Mutation
Keywords
RAG-17, SOD1 Gene Mutation, Amyotrophic Lateral Sclerosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RAG-17
Arm Type
Experimental
Arm Description
Doses of RAG-17 will range from a minimum of 60 mg to the maximum tolerated dose (MTD). Dosing once every two weeks, starting from 60 mg, with dose escalation. After reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months.
Intervention Type
Drug
Intervention Name(s)
RAG-17
Intervention Description
RAG-17 60mg is used
Primary Outcome Measure Information:
Title
Adverse events (AE) and serious adverse events (SAE)
Description
The incidence of adverse events (AE) and serious adverse events (SAE) within 180 days after RAG-17 treatment, and number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V5.0
Time Frame
Within 180 days after treatment
Title
Clinical laboratory examination index
Description
Monitor the abnormal change of clinical laboratory Index generated from general examination results before RAG-17 treatment, and within 180days after RAG-17 treatment, which including blood testing and urine testing. Eventually to determine the safety and tolerability of RAG-17 on adult ALS patients.
Time Frame
Before RAG-17 treatment and within 180 days after treatment
Title
Physiological Parameter-Vital Sign: Body Temperature
Description
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including body temperature in degree Celsius.
Time Frame
Within 180 days after treatment
Title
Physiological Parameter-Vital Sign: Pulse Rate
Description
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including pulse rate in beats per minute.
Time Frame
Within 180 days after treatment
Title
Physiological Parameter-Vital Sign: Respiration Rate
Description
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including respiration rate in breaths per minute.
Time Frame
Within 180 days after treatment
Title
Physiological Parameter-Vital Sign: Blood Pressure
Description
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including blood pressure in mmHg.
Time Frame
Within 180 days after treatment
Title
Physiological Parameter-Vital Signs: Height, Hip Circumference and Waist
Description
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital signs that are measured including height, hip circumference and waist in centimeter.
Time Frame
Within 180 days after treatment
Title
Physiological Parameter-Vital Signs: Weight
Description
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including body weight in kilogram.
Time Frame
Within 180 days after treatment
Title
Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)
Description
Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) is a questionnaire-based scale that is used to measure the change in functional impairment of adult ALS patients within 180 days after RAG-17 treatment. ALSFRS-R scale measures 12 aspects of physical function, and each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0.
Time Frame
Within 180 days after treatment
Title
Neurological examinations
Description
Incidence rate of abnormalities in neurological examinations within 180 days after RAG-17 treatment
Time Frame
Within 180 days after treatment
Title
Heart circulatory system examinations
Description
Incidence rate of abnormalities in heart circulatory system examinations within 180 days after RAG-17 treatment
Time Frame
Within 180 days after treatment
Title
Respiratory system examinations
Description
Incidence rate of abnormalities in respiratory system examinations within 180 days after RAG-17 treatment
Time Frame
Within 180 days after treatment
Title
Abdominal examinations
Description
Incidence rate of abnormalities in abdominal examinations within 180 days after RAG-17 treatment
Time Frame
Within 180 days after treatment
Title
ECG results
Description
Incidence rate of abnormalities in ECG results within 180 days after RAG-17 treatment
Time Frame
Within 180 days after treatment
Secondary Outcome Measure Information:
Title
SOD1 protein levels
Description
Changes of SOD1 protein levels in cerebrospinal fluid from baseline on day 1, day 15, day 29, day 60, day 120, day 180 and day 240 of adult ALS patients after RAG-17 treatment
Time Frame
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
Title
Plasma neurofilament light (NFL) levels
Description
Changes in plasma neurofilament light (NFL) levels from baseline on day 1, day 15, day 29, day 60, day 120, day 180 and day 240 in adult ALS patients after RAG-17 treatment
Time Frame
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
Title
Pharmacokinetic Changes of RAG-17
Description
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Maximum Observed Concentration (Cmax) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Time Frame
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
Title
Pharmacokinetic Changes of RAG-17
Description
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Time to Reach Maximum Observed Concentration (Tmax) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Time Frame
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
Title
Pharmacokinetic Changes of RAG-17
Description
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Time Frame
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
Title
Pharmacokinetic Changes of RAG-17
Description
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Time Frame
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
Title
Pharmacokinetic Changes of RAG-17
Description
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Apparent Terminal Elimination Half-life (t1/2) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
Time Frame
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
Title
Mechanical ventilation
Description
Time to invasive mechanical ventilation in adult ALS patients treated with RAG-17
Time Frame
From day1 to day240
Title
Death
Description
Time of death in adult ALS patients treated with RAG-17
Time Frame
From randomization date to date of death from any cause. The assessment period is up to 8 months
Other Pre-specified Outcome Measures:
Title
Lung function (including forced vital capacity)
Description
Changes in lung function (including forced vital capacity) in adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day 180
Time Frame
day 15, day 29, day 90, and day 180
Title
Severity of Fatigue (Fatigue Severity Scale - FSS)
Description
Fatigue Severity Scale(FSS) is a questionnaire-based scale that is used to measure the change in severity of fatigue in adult ALS patients on day 15, day 29, day 90, day 180 after RAG-17 treatment. FSS scale is 9-items questionnaire, and each item is scored on a 7 points scale from 1 (strongly disagree) to 7 (strongly agree). The minimum score in total is 9 points, and the maximum score possible is 63. The higher the score means the greater fatigue severity.
Time Frame
day 15, day 29, day 90, and day 180
Title
Muscle strength (Medical Research Council Scale - MRC Scale)
Description
Medical Research Council Scale (MRC Scale) is an assessment that is used to measure the change in muscle strength of abductor pollicis brevis muscle, abductor digiti minimi, and tibial anterior muscle in adult ALS patients treated with RAG-17 on day 15, day 29, day 90, day180. MRC Scales ranges from grade 0 to grade 5, where grade 0 means no muscle contraction, grade 5 means muscle has full strength.
Time Frame
day 15, day 29, day 90, and day 180
Title
Electromyography (EMG) measures
Description
Electromyography(EMG) is used to determine the functional performance of muscle and the index change including compound muscle action potential(CAMP)of EMG in adult ALS patients from baseline on day 29, day 90, and day180 after RAG-17 treatment
Time Frame
day 29, day 90, day 180
Title
Electromyography (EMG) Measures
Description
Changes in EMG measures (motor unit number index) from baseline on day 29, day 90, day180 after RAG-17 treatment in adult ALS patients
Time Frame
day 29, day 90, day 180
Title
Electromyography (EMG) Measures
Description
Changes in EMG measures (motor unit size index) from baseline on day 29, day 90, day180 after RAG-17 treatment in adult ALS patients
Time Frame
day 29, day 90, day 180
Title
7T magnetic resonance imaging measures
Description
7T magnetic resonance imaging (7T MRI) is used to measure the change in the value of body indexes in adult ALS patients treated with RAG-17 on day 29, day 90 and day180.
Time Frame
day 29, day 90 and day 180
Title
Kinetic Gait Analysis-Gait Function
Description
Kinetic gait analysis is used to determine the forces created by and during movement, and measurements are collected to further determine the change in gait functions of of adult ALS patients on day 15, day 29, day 90, and day180 after RAG-17 treatment.
Time Frame
day15, day 29, day 90, and day180
Title
Kinematic Gait Analysis-Gait Function
Description
Kinematic gait is studied via 3D motion analysis, Construction of the coordinates and orientation of the rigid body segments allow calculation of joint angles of the proximal and distal segment, joint angular velocity, and joint acceleration. Measurements are collected for each joint in all three cardinal planes of motion, and it further measures the change in gait functions of of adult ALS patients on day 15, day 29, day 90, and day180 after RAG-17 treatment.
Time Frame
day15, day 29, day 90, and day180
Title
Short Physical Performance Battery (SPPB) - Gait Function
Description
Short Physical Performance Battery (SPPB) is an objective assessment that is used to measure the change in gait functions including balance, lower extremity strength, and functional capacity of of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. The test includes three different assessments: walking, sit-to-stand and balance. A 0- to 12-point scale is used to score the sum of the three assessments with higher point values corresponding with greater levels of physical function and lower disability, and vise versa.
Time Frame
day 15, day 29, day 90, and day 180
Title
Scale for the Assessment and Rating of Ataxia (SARA) - First Item: Gait
Description
Scale for the Assessment and Rating of Ataxia (SARA) is a performance based scale that has eight categories to assess different impairments. The first category - gait of SARA is used to measure the change in gait function of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. Gait function is scored from 0point (normal) to 8points (unable to walk).
Time Frame
day 15, day 29, day 90, and day 180
Title
6-meter Walking Speed - Gait function
Description
6-meter walking speed is a performance test to assess walking speed over a short distance, which determine the changes in gait function of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. The test will be perform in 4 trials, as the first trial is practise trial, and the average of last three trials are calculated.
Time Frame
day 15, day 29, day 90, and day 180
Title
The Modified Norris Test Score - Functional ability
Description
The Modified Norris Test Score is a rating scale that is used to measure the change in functional ability of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. This scale is composed with two parts: the Limb Norris Scale (21 items) and the Norris Bulbar Scale (13 items), each item is scored from 0 point (cannot do anything) to 3 points (normal).
Time Frame
day 15, day 29, day 90, and day 180
Title
Amyotrophic Lateral Sclerosis Assessment Questionnaire -40 (ALSAQ-40) - The Quality of Life
Description
Amyotrophic Lateral Sclerosis Assessment Questionnaire -40 (ALSAQ-40) is a patient self-report health status PRO that is used to measure the changes in the quality of life of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180. There are 40 items in ALSAQ-40 with 5 domains: physical mobility (10 items), activities of daily living and independence (10 items), eating and drinking (3 items), communication (7 items), emotional reactions (10 items), each domain has a total score of 100 points, where 0 point means the worst health condition, and 100points means the best health condition.
Time Frame
day 15, day 29, day 90, and day 180
Title
The EuroQol 5 Dimension 5 Level (EQ-5D-5L)- The Quality of Life
Description
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-report survey that is used to measure the changes in the quality of life of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180. EQ-5D-5L contains 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each domain is scored on a 5-level severity from Level1(no difficulty) to Level5 (extreme difficulty).
Time Frame
day 15, day 29, day 90, and day 180
Title
Hamilton Anxiety Scale (HAM-A) - The Quality of Life
Description
Hamilton Anxiety Scale (HAM-A) is a rating scale that is used to measure the changes in severity of anxiety of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180. The scale is composed of 14 items, Each item is scored on a scale of 0 (no symptom) to 4 (severe), with a total score range of 0 to 56, where <7 means no symptom of anxiety, over 24 means mild to moderate severity, >29 means extreme severity.
Time Frame
day 15, day 29, day 90, and day 180
Title
Hamilton Depression Scale (HAM-D)-The Quality of Life
Description
Hamilton Depression Scale (HAM-D) is a rating scale that is used to measure the changes in severity of depression of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180. For the 17-item version, scores can range from 0 to 54. Scores between 0 and 6 indicate a normal person , scores between 7 and 17 indicate mild depression, scores between 18 and 24 indicate moderate depression, and scores over 24 indicate severe depression.
Time Frame
day 15, day 29, day 90, and day 180
Title
King's Staging System - Clinical staging of patients
Description
King's staging system is used to measure the change in clinical stages of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. The King's staging system consists of five disease stages, with Stage 5 being death. Stage 4 is nutritional failure.Stages 1-3 are based upon the number of El Escorial central nervous system (CNS) regions involved in the disease, measured by weakness, wasting, spasticity, dysphagia, or dysarthria.
Time Frame
day 15, day 29, day 90, and day 180
Title
The Milano-Torino (MiToS) Staging - Clinical staging of patients
Description
The Milano-Torino (MiToS) Staging is used to measure the change in clinical stages of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. The Milano-Torino (MiToS) Staging is composed with six stages, where stage 0 is no functional impairment, stage 1 is loss of one type of function, stage 2 is loss of two type of function, stage 3 is loss of three type of function, stage 4 is loss of four type of function, and stage 5 is death.
Time Frame
day 15, day 29, day 90, and day 180

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who are judged by professional medical staff to still be able to carry out the clinical trial project cycle; 18 years old ≤ age ≤ 75 years old, males or females; ALS patients with confirmed SOD1 gene mutations document (known SOD1 mutation sites and related disease progression have been reported); Forced vital capacity ≥ 80% of predicted vital capacity during the screening period; Diagnosis of confirmed or probable familial or sporadic ALS in accordance with the revised EI Escorial diagnostic criteria for amyotrophic lateral sclerosis of the World Federation of Neurology; The patient or patient's legal representative clearly understands and voluntarily participates in the study and signs the informed consent form; Subjects (including male subjects) are willing to have no birth plan and voluntarily take effective contraceptive measures during the entire study period and within 3 months after the end of the study, and have no plan to donate sperm or eggs. Exclusion Criteria: Patients with SOD1 mutations occurring at nucleotides 44 to 66 (calculated from the start of SOD1 protein translation), patients with P.F21C mutation; Patients who have previously received or are currently receiving Tofersen treatment; HIV test positive or history of positive tests; Positive hepatitis C virus antibody or history of positive tests; Active hepatitis B infection (positive hepatitis B surface antigen and/or positive hepatitis B core antibody); Have used other investigational drugs within 1 month or within 5 drug half-lives; Diseases and deformities of the lumbar spine; Have other conditions known to be associated with motor neuron dysfunction that may confuse or obscure an ALS diagnosis; Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent; With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value≥2.0 times the upper limit of normal value or AST value≥2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE≥1.5 times the upper limit of normal value or eGFR<40mL/min/1.73m2; severe cardiac insufficiency refers to NYHA class 3-4); Permanently dependent on ventilator-assisted ventilation; History of alcohol and drug abuse; Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant; Patients participating in other clinical trials or using other biological agents, drugs or devices under investigation; Patients who have received any vaccinations within 28 days; Contraindications to MRI (eg, claustrophobia); Unable to be cooperative and complete the follow-up due to other reasons.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
YiLong Wang
Organizational Affiliation
Beijing Tiantan Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beijing Tiantan Hospital
City
Beijing
ZIP/Postal Code
100050
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36116464
Citation
Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022 Oct 15;400(10360):1363-1380. doi: 10.1016/S0140-6736(22)01272-7. Epub 2022 Sep 15.
Results Reference
background
PubMed Identifier
26124198
Citation
Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y, Yang Y, Liu X, Ye S, Zhan S, Fan D. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1075-81. doi: 10.1136/jnnp-2015-310471. Epub 2015 Jun 29.
Results Reference
background
PubMed Identifier
29392461
Citation
Rosenbohm A, Liu M, Nagel G, Peter RS, Cui B, Li X, Kassubek J, Rothenbacher D, Lule D, Cui L, Ludolph AC; ALS Registry Swabia Study Group. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol. 2018 Apr;265(4):774-782. doi: 10.1007/s00415-018-8735-9. Epub 2018 Feb 1.
Results Reference
background
Citation
Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/amyotrophic-lateral-sclerosis-als-fact-sheet#treatment. October 2022.
Results Reference
background
PubMed Identifier
19822872
Citation
Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009 Oct 13;73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141. Erratum In: Neurology. 2009 Dec 15;73(24):2134. Neurology. 2010 Mar 2;74(9):781.
Results Reference
background
PubMed Identifier
34382759
Citation
Barrington CJ, Burruano M, Carney C, Choi J, Januska J, Lachuk L, Oskarsson B, Rodriguez C, Speicher L, Tereso G. Addressing the role of edaravone in the management of amyotrophic lateral sclerosis and gaps in care and access: expert panel recommendations. Am J Manag Care. 2021 Aug;27(12 Suppl):S231-S237. doi: 10.37765/ajmc.2021.88732.
Results Reference
background
PubMed Identifier
7180680
Citation
Emery AE, Holloway S. Familial motor neuron diseases. Adv Neurol. 1982;36:139-47. No abstract available.
Results Reference
background
PubMed Identifier
19271992
Citation
Chattopadhyay M, Valentine JS. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal. 2009 Jul;11(7):1603-14. doi: 10.1089/ars.2009.2536.
Results Reference
background
PubMed Identifier
27093948
Citation
Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, Bae JS, Hu CJ, Gourie-Devi M, Noto Y, Shibuya K, Goh KJ, Kaji R, Tsai CP, Cui L, Talman P, Henderson RD, Vucic S, Kiernan MC. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):821-30. doi: 10.1136/jnnp-2015-312751. Epub 2016 Apr 19.
Results Reference
background
PubMed Identifier
28700839
Citation
Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017 Jul 13;377(2):162-172. doi: 10.1056/NEJMra1603471. No abstract available.
Results Reference
background

Learn more about this trial

Safety and Tolerability of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation

We'll reach out to this number within 24 hrs